Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Clin Immunol. 2019 Aug 2;39(7):653–667. doi: 10.1007/s10875-019-00659-8

Figure 3.

Figure 3.

Cumulative incidence of acute GVHD grades I-IV (A), grades II-IV (B), and grades III-IV (C) in patients without IBD, in patients with IBD that was reported to be controlled, and patients with IBD that was reported to be uncontrolled prior to allogeneic HCT.